Stay updated with breaking news from Lenzilumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, Sept. 17, 2022 (GLOBE NEWSWIRE) WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen,. ....
Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus. | July 13, 2022 ....
Participants in the LIVE-AIR study with baseline CRP <150 mg/L treated with lenzilumab demonstrated a 62% reduction in the relative risk of invasive mechanical ventilation and death compared to placebo. ....
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that management will present and participate at multiple investors conferences in May 2022. Details of the conferences are as follows: ....
In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly1 Lenzilumab plus SOC resulted ....